taxonomy (1)
protein (1)
source (3)
structure (0)
composition (14)
disease (3)
reference (3)
site (1)
peptide (1)
- Homo sapiens (Human)
Taxonomy
Reported structure
- Hex:5 HexNAc:4 NeuAc:1 (avg mass : 1932.7652 )
- Hex:5 HexNAc:4 NeuAc:2 (avg mass : 2224.0231 )
- Hex:5 HexNAc:4 dHex:1 NeuAc:1 (avg mass : 2078.9082 )
- Hex:6 HexNAc:4 dHex:1 NeuAc:1 (avg mass : 2241.0506 )
- Hex:6 HexNAc:5 NeuAc:3 (avg mass : 2880.6184 )
- Hex:6 HexNAc:5 dHex:1 NeuAc:1 (avg mass : 2444.2456 )
- Hex:6 HexNAc:5 dHex:3 (avg mass : 2445.2737 )
- Hex:6 HexNAc:6 NeuAc:2 (avg mass : 2792.5555 )
- Hex:6 HexNAc:6 NeuAc:3 (avg mass : 3083.8134 )
- Hex:6 HexNAc:6 dHex:1 NeuAc:2 (avg mass : 2938.6985 )
- Hex:6 HexNAc:6 dHex:1 NeuAc:3 (avg mass : 3229.9564 )
- Hex:7 HexNAc:6 dHex:1 NeuAc:1 (avg mass : 2809.583 )
- Hex:7 HexNAc:6 dHex:2 NeuAc:1 (avg mass : 2955.726 )
- Hex:7 HexNAc:6 dHex:2 NeuAc:2 (avg mass : 3246.9839 )
Composition
- Cancer, breast (DOID:1612)
- Prostate cancer (DOID:10283)
- T-cell childhood acute lymphocytic leukemia (DOID:0080145)
Disease
- Glycoproteomic Analysis of MGL-Binding Proteins on Acute T-Cell Leukemia Cells. (2019 - Martina Pirro, Esmee Schoof, Sandra J. van Vliet, Yoann Rombouts, Alexandre Stella, Arnoud de Ru, Yassene Mohammed, Manfred Wuhrer, Peter A. van Veelen, Paul J. Hensbergen) / Status : Reviewed
- Large-scale intact glycopeptide identification by Mascot database search (2018 - Ravi Chand Bollineni, Christian Jeffrey Koehler, Randi Elin Gislefoss, Jan Haug Anonsen, Bernd Thiede) / Status : Unreviewed
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
Reference
- Receptor-type tyrosine-protein phosphatase C / Homo sapiens
Reported glycosite
- YANITVDYLYNK (12aa)
Mass spectrometry observed peptide
-
- Hex:5 HexNAc:4 NeuAc:1 / N-Linked (avg mass : 1932.7652)
- Blood Serum (UBERON_0001977)
- Prostate cancer (DOID:10283)
- Receptor-type tyrosine-protein phosphatase C / Homo sapiens
- YANITVDYLYNK (12aa)
-
- Hex:5 HexNAc:4 dHex:1 NeuAc:1 / N-Linked (avg mass : 2078.9082)
- Mammary Gland (UBERON_0001911)
- Cancer, breast (DOID:1612)
- Receptor-type tyrosine-protein phosphatase C / Homo sapiens
- YANITVDYLYNK (12aa)
-
- Hex:5 HexNAc:4 NeuAc:2 / N-Linked (avg mass : 2224.0231)
- Blood Serum (UBERON_0001977)
- Prostate cancer (DOID:10283)
- Receptor-type tyrosine-protein phosphatase C / Homo sapiens
- YANITVDYLYNK (12aa)
-
- Hex:6 HexNAc:4 dHex:1 NeuAc:1 / N-Linked (avg mass : 2241.0506)
- Blood Serum (UBERON_0001977)
- Prostate cancer (DOID:10283)
- Receptor-type tyrosine-protein phosphatase C / Homo sapiens
- YANITVDYLYNK (12aa)
-
- Hex:6 HexNAc:5 dHex:1 NeuAc:1 / N-Linked (avg mass : 2444.2456)
- Glycoproteomic Analysis of MGL-Binding Proteins on Acute T-Cell Leukemia Cells. (2019 - Martina Pirro, Esmee Schoof, Sandra J. van Vliet, Yoann Rombouts, Alexandre Stella, Arnoud de Ru, Yassene Mohammed, Manfred Wuhrer, Peter A. van Veelen, Paul J. Hensbergen) / Status : Reviewed
- Reanalysis of global proteomic and phosphoproteomic data identified a large number of glycopeptides (2018 - Yingwei Hu, Punit Shah, David J. Clark, Minghui Ao, Hui Zhang) / Status : Unreviewed
- Receptor-type tyrosine-protein phosphatase C / Homo sapiens
- YANITVDYLYNK (12aa)
-
- Hex:6 HexNAc:5 dHex:3 / N-Linked (avg mass : 2445.2737)
- Jurkat (CVCL_0065)
- Receptor-type tyrosine-protein phosphatase C / Homo sapiens
- YANITVDYLYNK (12aa)
-
- Hex:6 HexNAc:6 NeuAc:2 / N-Linked (avg mass : 2792.5555)
- Blood Serum (UBERON_0001977)
- Prostate cancer (DOID:10283)
- Receptor-type tyrosine-protein phosphatase C / Homo sapiens
- YANITVDYLYNK (12aa)
-
- Hex:7 HexNAc:6 dHex:1 NeuAc:1 / N-Linked (avg mass : 2809.583)
- Jurkat (CVCL_0065)
- Receptor-type tyrosine-protein phosphatase C / Homo sapiens
- YANITVDYLYNK (12aa)
-
- Hex:6 HexNAc:5 NeuAc:3 / N-Linked (avg mass : 2880.6184)
- Blood Serum (UBERON_0001977)
- Prostate cancer (DOID:10283)
- Receptor-type tyrosine-protein phosphatase C / Homo sapiens
- YANITVDYLYNK (12aa)
-
- Hex:6 HexNAc:6 dHex:1 NeuAc:2 / N-Linked (avg mass : 2938.6985)
- Blood Serum (UBERON_0001977)
- Prostate cancer (DOID:10283)
- Receptor-type tyrosine-protein phosphatase C / Homo sapiens
- YANITVDYLYNK (12aa)
-
- Hex:7 HexNAc:6 dHex:2 NeuAc:1 / N-Linked (avg mass : 2955.726)
- Blood Serum (UBERON_0001977)
- Prostate cancer (DOID:10283)
- Receptor-type tyrosine-protein phosphatase C / Homo sapiens
- YANITVDYLYNK (12aa)
-
- Hex:6 HexNAc:6 NeuAc:3 / N-Linked (avg mass : 3083.8134)
- Blood Serum (UBERON_0001977)
- Prostate cancer (DOID:10283)
- Receptor-type tyrosine-protein phosphatase C / Homo sapiens
- YANITVDYLYNK (12aa)
-
- Hex:6 HexNAc:6 dHex:1 NeuAc:3 / N-Linked (avg mass : 3229.9564)
- Blood Serum (UBERON_0001977)
- Prostate cancer (DOID:10283)
- Receptor-type tyrosine-protein phosphatase C / Homo sapiens
- YANITVDYLYNK (12aa)
-
- Hex:7 HexNAc:6 dHex:2 NeuAc:2 / N-Linked (avg mass : 3246.9839)
- Blood Serum (UBERON_0001977)
- Prostate cancer (DOID:10283)
- Receptor-type tyrosine-protein phosphatase C / Homo sapiens
- YANITVDYLYNK (12aa)
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
